BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

BioLife Solutions Inc.

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on BioLife Solutions today. The company’s shares opened today at $27.44. According to TipR...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BLFS	$26.53	+9.63%	540.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BLFS	$26.53	+9.6%	540.12K
3
4
5
6

BLFS

BLFS

Dividend Overview

Get BioLife Solutions Inc. Data in Excel

Get BioLife Solutions Inc. Data in Excel